tbuckley/cabot-search huggingface dataset:
OP0029 Clinical effect of vedolizumab on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease
Authors: J. Paccou, M. Nachury, C. Duchemin, P. Desreumaux, R.-M. Flipo, B. Pariente
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Data on the effects of vedolizumab on joint manifestations remain controversial.<sup>1,2</sup> <h3>Objectives</h3> The purpose of this study was to<sup><sup>1</sup></sup> evaluate baseline characteristics of crohn's disease (CD) and ulcerative colitis (UC) patients treated with vedolizumab,<sup><sup>2</sup></sup> assess the effect of vedolizumab on joint manifestations in patients with inflammatory bowel disease (IBD)-associated Spondyloarthritis (SpA), and<sup><sup>3</sup></sup> evaluate new onset of SpA under VDZ. <h3>Methods</h3> This single-centre, retrospective and observational study was conducted from July 2014 to July 2017. The charts of all patients with IBD who had undergone treatment with vedolizumab for more than 3 months were reviewed. The patients' demographic and clinical characteristics were collected. Data on IBD-associated SpA were collected as well as new onset of SpA under VDZ. The ASAS criteria were used to establish the diagnosis of SpA. <h3>Results</h3> Patient characteristics and main results are shown in table 1. A total of 171 patients diagnosed with IBD were treated with vedolizumab from July 2014 to July 2017. Notably, 97.1% of patients had been previously treated with at least one TNF-α inhibitor. All patients included in this study completed the induction phase at last observation, and the mean follow-up of the entire cohort was 14.3±12.0 months. Ten (5.8%) patients had a history of IBD-associated SpA but were in clinical remission at the time of initiation of VDZ, whereas 4 (2.4%) had active SpA when VDZ was started. First, no clinical benefit on SpA following initiation of VDZ was found in those 4 patients with active SpA. Second, exacerbation of SpA in patients with clinical remission at initiation of VDZ was found in 6/10 patients whereas no effect was reported in the remaining 4/10 patients. All those 14 patients with IBD-associated SpA were under TNF inhibitors just before starting VDZ. Finally, new onset of SpA induced by VDZ was reported in 1 patient. <h3>Conclusions</h3> Vedolizumab does not seem to show any efficacy in IBD-associated SpA and might even induce exacerbation or new onset of SpA. Inception cohort studies are needed to better evaluate the effect of vedolizumab on joint manifestations. <h3>References</h3> [1] Varkas G, Thevissen K, De Brabanter G, et al. Ann Rheum Dis2017May;76(5):878–881. [2] Orlando A, Orlando R, Ciccia F, et al. Ann Rheum Dis2017Sep;76(9):e31. <h3>Disclosure of Interest</h3> None declared
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial
Authors: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, Herbert Rübben, Peter Albers, Johannes M. Wolff, Detlef Frohneberg, Patrick de Geeter, Axel Heidenreich, Tilman Kälble, Michael Stöckle, Thomas Schnöller, Arnulf Stenzl, Markus Müller, Michael Truss, Stephan Roth, Uwe-Bernd Liehr, Joachim Leißner, Thomas Bregenzer, Margitta Retz
Journal: European Urology (2018)
Chromatin run-on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme
Authors: Tinyi Chu, Edward J. Rice, Gregory T. Booth, H. Hans Salamanca, Zhong Wang, Leighton J. Core, Sharon L. Longo, Robert J. Corona, Lawrence S. Chin, John T. Lis, Hojoong Kwak, Charles G. Danko
Journal: Nature Genetics (2018)
Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy
Authors: Muharrem Muftuoglu, Amanda Olson, David Marin, Sairah Ahmed, Victor Mulanovich, Sudhakar Tummala, T. Linda Chi, Alessandra Ferrajoli, Indreshpal Kaur, Li Li, Richard Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Journal: New England Journal of Medicine (2018)

JC virus, the cause of progressive multifocal leukoencephalopathy (PML), and the BK virus are genetically similar and share sequence homology in immunogenic proteins. We treated three immunosuppressed patients with PML with ex vivo-expanded, partially HLA-matched, third-party-produced, cryopreserved BK virus-specific T cells. The immunosuppression in these patients was due to the conditioning regimen for cord-blood transplantation in one patient, a myeloproliferative neoplasm treated with ruxolitinib in another, and acquired immunodeficiency syndrome in the third. After T-cell infusion in two of the patients, alleviation of the clinical signs and imaging features of PML was seen and JC virus in the cerebrospinal fluid (CSF) cleared. The other patient had a reduction in JC viral load and stabilization of symptoms that persisted until her death 8 months after the first infusion. Two of the patients had immune reconstitution syndrome. Donor-derived T cells were detected in the CSF after infusion. (Funded by the M.D. Anderson Cancer Center Moon Shots Program and the National Institutes of Health; ClinicalTrials.gov number, NCT02479698 .).
Idiopathic Inflammatory Myopathy and Antisynthetase Syndrome
Authors: Paula Fernández-Rodríguez, Juan José Martín-Marcuartu, Jose Manuel Jiménez-Hoyuela
Journal: Clinical Nuclear Medicine (2018)

We present a 44-year-old woman with scapular and pelvic muscle weakness, joint inflammation, and fever. Bone scintigraphy showed high uptake in proximal regions of upper and lower limbs, suspecting inflammatory myopathy and polyarticular damage. These features were the clue to request other complementary tests such as anti-aminoacyl-tRNA-synthetase antibodies and chest CT, which showed interstitial lung disease, defining an antisynthetase syndrome. Therefore, BS allows an earlier diagnosis of inflammatory muscle disease and to identify the optimal site for muscle biopsy. BS is an important step to reach a prompt diagnosis of antisynthetase syndrome for establishing an early treatment.
SAT0618 Relationship between arterial stiffness and disease duration in behcet’s disease
Authors: K. Ayar, B. Sensoy, M.E. Aslanci, T. Teker, S. Cekic
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There are few studies in the literature investigating arterial stiffness in Behcet's Disease (BD). The association of arterial stiffness with duration of disease is unknown. <h3>Objectives</h3> The aim of this study is to compare arterial stiffness by assessing pulse wave velocity (PWV) and augmentation index (AI) measurements in healthy controls (HC) and patients diagnosed as BD with low and high disease duration. <h3>Methods</h3> Seventy BD patients and 40 HC without diabetes mellitus, Hipertension or chronic renal failure were included in the study. Patients with BD who were diagnosed within 12 months were taken to the group with low disease duration (LDD) and the others to the group with high disease duration (HDD). Demografic data and lipid parameters of all participants were recorded and PWV and AI measurements were made from brachial artery. The clinical charecteristics of the patients with BD were recorded and the Behcet's Syndrome Activity Scale (BSAS) questionnaire was filled in for all patients with BD. Findings were compared between LDD, HDD and HC groups. <h3>Results</h3> Age, gender and body mass indexes were not statistically different between groups (p=0.134, p=0.948, p=0.929 respectively). Augmentation index and PWV measurements were different between groups (p=0.014, p=0.024 respectively). In the HDD group, both PWV and AI were significantly higher than HC (p=0.013, p=0.006 respectively). In LDD group AI was significantly higher than HC however PWV was not (p=0.047, p=0.919 respectively). There was moderate coralation between PWV and disease duration (Rho:0.393; p&lt;0.001) and there was no coralation between AI and disease duration (p=0.287) <h3>Conclusions</h3> The augmentation index is higher in patients with BD than HC regardless of the duration of the disease. Pulse wave velocity does not increase in the early period of the disease in patients with BD but increases with prolonged desease duration. <h3>References</h3> [1] Yilmaz S1, Celik G, Esmen SE. Assessment of arterial stiffness in patients with inactive and active Behçet's disease. Scand J Rheumatol. 2014;43(1):63–9. doi:10.3109/03009742.2013.809787. Epub 2013 Sep 9 [2] Yildirim A1, Karakaş MS2, Kilinç AY3, Altekin RE3, Yalçinkaya AS3. Evaluation of arterial stiffness and subclinical atherosclerosis in patients with Behçet's disease without cardiovascular involvement. Turk Kardiyol Dern Ars2016;Oct;44(7):575–581. doi:10.5543/tkda.2016.06944 <h3>Disclosure of Interest</h3> None declared
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501–9
Authors: So-Ryoung Lee, Byoung-Won Park, Jae Heon Kim
Journal: European Urology (2018)
9-ING-41, a clinically relevant inhibitor of glycogen synthase kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers
Authors: H. Kuroki, T. Anraku, V. Bilim, M. Tasaki, D. Schmitt, A. Mazar, A. Ugolkov, Y. Tomita
Journal: Annals of Oncology (2018)
Central Sensitization in Knee Osteoarthritis: Relating Presurgical Brainstem Neuroimaging and Pain<scp>DETECT</scp>‐Based Patient Stratification to Arthroplasty Outcome
Authors: Anushka Soni, Vishvarani Wanigasekera, Melvin Mezue, Cyrus Cooper, Muhammad K. Javaid, Andrew J. Price, Irene Tracey
Journal: Arthritis & Rheumatology (2018)

The neural mechanisms of pain in knee osteoarthritis (OA) are not fully understood, and some patients have neuropathic-like pain associated with central sensitization. To address this, we undertook the present study in order to identify central sensitization using neuroimaging and PainDETECT and to relate it to postarthroplasty outcome.
Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers
Authors: Perry V. Halushka, Andrew J. Goodwin, Marc K. Halushka
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Cardiovascular diseases exist across all developed countries. Biomarkers that can predict or diagnose diseases early in their pathogeneses can reduce their morbidity and mortality in afflicted individuals. microRNAs are small regulatory RNAs that modulate translation and have been identified as potential fluid-based biomarkers across numerous maladies. We describe the current state of cardiovascular disease biomarkers across a range of diseases, including myocardial infarction, acute coronary syndrome, myocarditis, hypertension, heart failure, heart transplantation, aortic stenosis, diabetic cardiomyopathy, atrial fibrillation, and sepsis. We present the current understanding of microRNAs as possible biomarkers in these categories and where their best opportunities exist to enter clinical practice.
Abstract 17886: Impact of a Very Early Invasive Strategy in High Risk NSTEMI: Analysis From the TAO (Treatment for Acute Coronary Syndromes With Otamixaban) Trial
Authors: Pierre Deharo, Gregory Ducrocq, Christoph Bode, Marc Cohen, Thomas Cuisset, Shamir Mehta, Charles Pollack, Stephen Wiviott, Yedid Elbez, Marc Sabatine, Phillipe Gabriel Steg
Journal: Circulation (2016)

Introduction: In patients with NSTEMI and GRACE score > 140, coronary angiography (CAG) with a view to revascularization is recommended within 24h. Whether further reducing time to CAG is beneficial in this population remains unclear. Hypothesis: We sought to compare the impact of a “very early” (i.e. within 12 hours after admission), early (12-24h) and standard (>24h) CAG in patients hospitalized for NSTEMI and with GRACE score >140. Methods: The TAO trial randomized individuals with moderate to high-risk NSTEMI and CAG scheduled within the first 72 hours to heparin plus eptifibatide versus otamixaban. Otamixaban did not reduce the rate of ischemic events but did increase bleeding. Patients with GRACE score > 140 and undergoing CAG were stratified in 3 groups according to timing of CAG from the first ECG performed on admission (≤12h, 12 to 24h, >24h). The primary outcome was defined by the composite of all-cause death and MI at 180 days. Analyses were adjusted on age, gender, diabetes mellitus, prior PCI...
3D cell-laden polymers to release bioactive products in the eye
Authors: Gorka Orive, Edorta Santos-Vizcaino, Jose Luis Pedraz, Rosa Maria Hernandez, Julia E. Vela Ramirez, Alireza Dolatshahi-Pirouz, Ali Khademhosseini, Nicholas A. Peppas, Dwaine F. Emerich
Journal: Progress in Retinal and Eye Research (2018)
Plasma vs Tissue Next-Generation Sequencing in Non–Small Cell Lung Cancer—Either, Both, or Neither?
Authors: Bishal Gyawali, Howard (Jack) West
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Restoring Endothelial Function by Targeting Desert Hedgehog Downstream of Klf2 Improves Critical Limb Ischemia in Adults
Authors: Caroline Caradu, Thierry Couffinhal, Candice Chapouly, Sarah Guimbal, Pierre-Louis Hollier, Eric Ducasse, Alessandra Bura-Rivière, Mathilde Dubois, Alain-Pierre Gadeau, Marie-Ange Renault
Journal: Circulation Research (2018)

Klf (kruppel-like factor) 2 is critical to establish and maintain endothelial integrity.Therefore, determining upstream and downstream mediators of Klf2 would lead to alternative therapeutic targets in cardiovascular disease management.Here we identify Dhh (desert hedgehog) as a downstream effector of Klf2, whose expression in endothelial cells (ECs) is upregulated by shear stress and decreased by inflammatory cytokines. Consequently, we show that Dhh knockdown in ECs promotes endothelial permeability and EC activation and that Dhh agonist prevents TNF-α (tumor necrosis factor alpha) or glucose-induced EC dysfunction. Moreover, we demonstrate that human critical limb ischemia, a pathological condition linked to diabetes mellitus and inflammation, is associated to major EC dysfunction. By recreating a complex model of critical limb ischemia in diabetic mice, we found that Dhh-signaling agonist significantly improved EC function without promoting angiogenesis, which subsequently improved muscle perfusion.Restoring EC function leads to significant critical limb ischemia recovery. Dhh appears to be a promising target, downstream of Klf2, to prevent the endothelial dysfunction involved in ischemic vascular diseases.
Abstract 12172: Development and Preliminary Evaluation of an Avatar-based Educational Application for Improving Knowledge on Symptom Recognition and Management in Patients With Acute Coronary Syndromes
Authors: Jintana Tongpeth, Hui Y Du, Robyn A Clark
Journal: Circulation (2016)

Background: A poor understanding of what are the symptoms of a heart attack is recognized as a major obstacle to timely medical treatment and it is associated with potentially preventable death and complications. Numerous studies have demonstrated that information technology plays an important role in improving patients’ knowledge and self-management ability. Purpose: To develop and evaluate the acceptability of an avatar-based education application for teaching chest pain recognition and management, among people who are at risk of a heart attack Methods: In phase one, a participatory action research method was used to develop the application. The development phase involved working with clinical experts, IT experts and consumers through two cycles of development and critical reflection. In phase 2, a pre and post design was used to assess the acceptability and effect of application on a sample of patients with acute coronary syndrome (ACS). Patients’ knowledge, attitude, belief and satisfaction were measured using the ACS Response Index. Results: The avatar-based education application involves illustration, concepts and quizzes which were developed for teaching chest pain recognition and management, among people who are at risk of a heart attack. Consumers feedback focused on usability, ease of navigation and encourage both learning and enjoyment. The application was tested on ten patients (mean age 52.2±10.4 years) with acute coronary syndrome. A high level of user satisfaction (87.3%) was reported. The knowledge score of the ACS response index increased from 62.4 (±13.4%) to 78.1 (±9.3%), the belief scores increased by 25.7% (73.2±6.1% to 98.9±1.7%) and symptom recognition scores increased by 24.3 % (72.5±5.6% to 96.8±8.0%). Conclusion: This study suggested that a multidisciplinary collaboration was effective in developing patient education intervention. The positive outcomes of this study will lead to a randomised trial to test the effectiveness of this intervention.
Triggering antitumoural drug release and gene expression by magnetic hyperthermia
Authors: María Moros, Javier Idiago-López, Laura Asín, Eduardo Moreno-Antolín, Lilianne Beola, Valeria Grazú, Raluca M. Fratila, Lucía Gutiérrez, Jesús Martínez de la Fuente
Journal: Advanced Drug Delivery Reviews (2018)
Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors
Authors: M.O. Butler, H. Majeed, M. Nelles, S. Saibil, L. Bonilla, S. Boross-Harmer, V. Sotov, S. Elston, K. Ross, B. van As, M. Le, M. Fyrsta, C. Lo, J. Yam, J. Nie, L. Scheid, P. Ohashi, L. Nguyen, S. Tanaka, N. Hirano
Journal: Annals of Oncology (2018)
Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy
Authors: Yang Zhang, Kun Ling Ma, Yu Xiang Gong, Gui Hua Wang, Ze Bo Hu, Liang Liu, Jian Lu, Pei Pei Chen, Chen Chen Lu, Xiong Zhong Ruan, Bi Cheng Liu
Journal: Journal of the American Society of Nephrology (2018)

Background Glomerular endothelium dysfunction, which plays a crucial role in the pathogenesis of early diabetic nephropathy, might be caused by circulating metabolic abnormalities. Platelet microparticles, extracellular vesicles released from activated platelets, have recently emerged as a novel regulator of vascular dysfunction. Methods We studied the effects of platelet microparticles on glomerular endothelial injury in early diabetic nephropathy in rats with streptozotocin-induced diabetes and primary rat glomerular endothelial cells. Isolated platelet microparticles were measured by flow cytometry. Results Plasma platelet microparticles were significantly increased in diabetic rats, an effect inhibited in aspirin-treated animals. In cultured glomerular endothelial cells, platelet microparticles induced production of reactive oxygen species, decreased nitric oxide levels, inhibited activities of endothelial nitric oxide synthase and SOD, increased permeability of the glomerular endothelium barrier, and reduced thickness of the endothelial surface layer. Conversely, inhibition of platelet microparticles in vivo by aspirin improved glomerular endothelial injury. Further analysis showed that platelet microparticles activated the mammalian target of rapamycin complex 1 (mTORC1) pathway in glomerular endothelial cells; inhibition of the mTORC1 pathway by rapamycin or raptor siRNA significantly protected against microparticle-induced glomerular endothelial injury in vivo and in vitro . Moreover, platelet microparticle–derived chemokine ligand 7 (CXCL7) contributed to glomerular endothelial injury, and antagonizing CXCL7 using CXCL7-neutralizing antibody or blocking CXCL7 receptors with a competitive inhibitor of CXCR1 and CXCR2 dramatically attenuated such injury. Conclusions These findings demonstrate a pathogenic role of platelet microparticles in glomerular endothelium dysfunction, and suggest a potential therapeutic target, CXCL7, for treatment of early diabetic nephropathy.
Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement
Authors: Antonio Madruga Neto, Vitor Brunaldi, Ossamu Okazaki, Marco Santo Filho, Antônio Miranda Neto, Vera Anapaz, Eduardo de Moura
Journal: Endoscopy (2018)

Leaks are serious complications after sleeve gastrectomy, with an incidence rate up to 7 % [1]. Currently, stent placement and other endoscopic techniques are recommended for the treatment of post-bariatric leaks (PBLs) [2]. Bariatric stents are a feasible, effective and life-saving method [3]. They achieve leak closure rates between 72.8 % and 87.8 % but are associated with significant migration rates (16.9 % – 28.2 %) [1] [4]. The large bariatric-specific stent (LBSS) has been developed as an important device to fit bariatric anatomy and avoid migration because of its long length with the distal edge being placed in the duodenum [5].
The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients
Authors: C. Lisanti, D. Basile, S.K. Garattini, G. Pelizzari, A. Parnofiello, F. Cortiula, E. Ongaro, M. Cattaneo, C. Corvaja, V.J. Andreotti, M. Bartoletti, M. Casagrande, D. Iacono, M. Bonotto, P. Ermacora, N. Pella, A. Buonadonna, F. Puglisi, G. Fasola, G. Miolo
Journal: Annals of Oncology (2018)